Sobi to acquire Arthrosi Therapeutics

Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, has entered into a definitive agreement to acquire San Diego, USA-based biotech Arthrosi Therapeutics, a private late-stage biotechnology company focused on developing a next-generation treatment for gout.

The acquisition strengthens Sobi’s gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase III clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi’s pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies.

The Swedish company recently had its biologics license application (BLA) for nanoencapsulated sirolimus plus pegadricase (NASP) to treat uncontrolled gout accepted for review by the US Food and Drug Administration, which has set a decision date of June 27, 2026, under the Prescription Drug User Fee Act.